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ABSTRACT
Objective To investigate salivary cortisol samples in
patients with Parkinson’s disease (PD) with and without
impulsive compulsive behaviours (ICB) during a risk task.
Methods Salivary cortisol levels were measured in 13
PD patients without ICB (PD ICB) and in 15 PD patients
with ICB (PD+ICB) before, after medication and
throughout the day, and were compared with results
with 14 healthy controls. All participants also performed
a gambling task to assess risk taking behaviour.
Results Signiﬁcantly higher diurnal cortisol levels were
found in the PD ICB group compared with healthy
controls but no differences were seen between the
PD+ICB and the control group. Increased cortisol levels
were signiﬁcantly correlated with increased risk taking in
PD+ICB patients but no interaction was found in the
PD ICB group.
Conclusions The ﬁndings are in keeping with previous
studies which have linked low cortisol levels with
antisocial behaviour. The higher cortisol levels during the
risk task in the PD+ICB group are consistent with
reports in pathological gamblers during gambling and
addicts during drug abuse. The results support the
hypothesis that cortisol plays an important role in risk
taking in ICBs.
The cause of Parkinson’s disease (PD) remains
unknown but acute severe stress has been
suggested as a possible precipitant.
1 Elevated
cortisol levels in animal models of PD have been
associated with dopaminergic cell loss and motor
handicap.
2 Higher cortisol levels have been
described in depression,
3 anxiety
4 and also in
Alzheimer’s disease and PD.
5 An acute increase in
cortisol levels has been reported during intake of
illicit drugs.
6 Although a large proportion of
addiction related research has highlighted the
importance of dopaminergic pathways,
7 there is
also a line of evidence supporting the role of cortisol
in the development of addictive or impulsive
behaviours.
89
A subgroup of PD patients develop impulsive
compulsive behaviours (ICB) which are associated
with antisocial behaviour.
10 ICBs are usually trig-
gered by dopamine agonist therapy and there is
growing evidence linking the aetiology of these
ICBs to the development of drug addictions.
11 12
Previous studies have found lower cortisol levels in
impulsive non-PD participants.
13 14 Given the link
between cortisol and addiction in healthy subjects,
and between addiction and the development of
ICBs in PD patients, we hypothesised that cortisol
levels might be reduced in PD patients with ICBs,
relative to PD patients without ICBs.
For this study, we measured salivary cortisol
levels from PD patients with (PD+ICB) and
without (PD ICB) ICBs, and healthy controls, and
correlated these results with their performance on
a risk task.
15 Increased salivary cortisol levels have
also been positively correlated with risk taking in
non-PD pathological gamblers.
16 Therefore, we
sought to correlate cortisol with risk taking behav-
iour, having previously shown increased risk taking
in gambling tasks in all PD patients on medication
compared with controls, with highest risk taking
behaviour in PD patients with pathological
gambling.
17
METHODS
Participants
Cortisol samples from 13 PD ICB, 15 PD+ICB
patients and 14 healthy controls were collected. All
patients were recruited from the National Hospital
for Neurology and Neurosurgery, Queen Square,
London, fulﬁlling the Queen Square Brain Bank
criteria for PD
18 and were taking L-dopa. PD+ICB
patients were diagnosed using proposed
criteria.
19e21 Most PD+ICB patients had more
than one ICB. Healthy controls were usually
recruited from among the patient’s partners and
were not taking any medication that could inﬂu-
ence cortisol measurement. None of the partici-
pants was taking steroids. Written informed
consent was obtained from all subjects according to
approved ethical protocols from the regional and
local research ethics committee.
We excluded participants who scored under 27/
30 points on the Mini-Mental State Examination
and who had a current or past medical history of an
anxiety disorder, and patients with current
depression. Patients without a known previous
diagnosis of anxiety or depression were screened for
these conditions in a semi-structured clinical
assessment. Furthermore, all participants were
asked to complete the positive and negative affect
schedule which has been recommended as
a supplement to measure anxiety and depression.
22
Samples were obtained in a quiet environment,
usually at the patient’s home, to control for and
reduce the amount of stress.
To control for the potential effects of food
23 and
L-dopa
24 on cortisol levels, PD patients were asked
not to take their usual anti-Parkinson medication
for at least 12 h and not to have breakfast on the
day of testing. All participants woke up between
6:00 and 7:00. The morning samples were obtained
together with the researcher and the other samples
were collected by the participants themselves.
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Participants were instructed to collect saliva samples by turning
the cotton roll for 2e3 min in their mouth. In total, ﬁve saliva
samples were collected from controls and 10 samples from
patients. Samples from all participants were obtained between
8:15 and 8:45dbaseline level. All patients were tested in their
‘off condition’ in the morning, which was assessed by the
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) part 3 motor
score. Furthermore, we collected ﬁve more saliva samples from
the patient group. One was obtained immediately prior to the
risk task, one just after the risk test and prior to medication, the
next 5 min after medication, then 15 min after medication,
30 min after medication and 45 min after medication. Sixty
minutes after medication, between 9:15 and 9:45 and after the
second test (‘on condition’ in patients), another sample was
taken, this time from both controls and patients (ﬁgure 1).
All participants then collected samples between 13:00 and
14:00, between 19:00 and 20:00 and between 22:00 and 23:00 on
their own. These times were deliberately ﬂexible for patients to
ensure that the cortisol sampling was undertaken approximately
1 h after taking their usual dopamine replacement therapy.
Controls were tested in the same way without taking any
medication in between.
Subjects were asked to avoid excessive physical activity, stress
and heavy meals on the study day, and were provided with
a collection diary where they entered the time of saliva collec-
tion and their activity during the hour prior to each cortisol
sample. In addition, participants were instructed not to eat
anything at least 30 min prior to collecting a sample.
The therapeutic motor response to L-dopa was assessed by
UPDRS scores (part 3) during ‘off’ and ‘on’ states. All patients
had an excellent L-dopa response and had a similar improvement
in UPDRS scores. All patients were ‘on’ at the time of the second
risk task. Levodopa equivalent units (LEU) was calculated as
described previously
21 (see table 1 for demographic information).
Risk task
All patients were tested on a validated computerised gambling
task to assess risk behaviour
15 once in their ‘off medication’ state
after their ﬁrst salivary cortisol sampling, and once in their ‘on
medication’ state approximately 50 min after receiving their
usual morning anti-Parkinson medications. Controls were tested
in the same way but did not take dopaminergic medication
between the tests. Participants had to choose between two
gambles with varying levels of risksdeither a low risk or a high
risk gamble, where participants could win real money. Feedback
was given immediately. Details about this task are published
elsewhere.
17 Risk aversion was assessed parametrically by ﬁtting
a model to each participant’s behaviour, separately for each test
session.
17
Biochemical measurements
Saliva samples for the determination of cortisol concentration
were collected in Salivettes (Sarstedt, Leicester, UK) and stored
at  208C until analysed. Details on the analysis were published
recently elsewhere.
25
Statistical analysis
Demographic and clinical features
Data analyses were performed using SPSS V.18. Age, gender, age
of onset, UPDRS scores, L-dopa and LEU dose were used as
dependent variables and group (PD ICB, PD+ICB and control)
was modelled as a between subject factor. We used ANOVA, the
Student’s t test or the c
2 test where appropriate.
Cortisol salivary samples
The data were positively skewed as cortisol levels show a diurnal
variation with a peak during the morning (ﬁgure 2). As a result,
we log transformed the data and residuals were checked and
found to be normally distributed. We performed a linear mixed
model ANOVA with the log transformed scores as the depen-
dent variable and group (PD ICB, PD+ICB and control) was
modelled as a between subject factor. The model also included
subject as a random factor, and the interactions between the
two ﬁxed factors (time and group). All post hoc comparisons
were corrected by the Bonferroni method; the level of signiﬁ-
cance was p<0.05. For the diurnal cortisol measurement we
excluded those extra samples that were obtained from the
patients between the tests.
We correlated the change in risk aversion with the change in
cortisol levels. This is a within subjects analysis. Speciﬁcally, we
calculated the correlation coefﬁcient between: DR and DC,
where DR¼R1eR2 is the difference in risk aversion in the ﬁrst
and second test session; DC was deﬁned accordingly for cortisol
levels. One value for DR and one for DC was derived for each
subject, and these values were then correlated using Pearson’s
correlation test.
RESULTS
Demographic characteristics
The groups were generally well matched. There was no signiﬁ-
cant age difference between the groups (F(2,38)¼2.5, p¼0.091).
However, PD+ICB patients had an earlier disease onset (t24¼2.6,
p¼0.014). There was no difference in the daily L-dopa doses or
the dose given in the morning, LEU dose, UPDRS (part 3 motor)
scores or disease duration (see table 1 for further details).
Figure 1 Schematic outline of the
time course of saliva samples. Ten
samples were taken from Parkinson’s
disease (PD) patients prior to
medication (‘off’) and after medication
(‘on’). Five samples were obtained from
controls.
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We found a main effect of group (F(2,37)¼4.6, p¼0.016) and
a main effect of time (F(4,144)¼51.0, p<0.001), with the highest
cortisol level being in the morning. There was no interaction
between time and group (F(8,144)¼0.9, p¼0.48). Post hoc analysis
revealed that the PD ICB group had signiﬁcantly higher cortisol
levels than the control group (p¼0.019) (ﬁgure 3). There was no
difference between the control and PD+ICB group (p¼0.1) and
no difference between the patient groups (p¼1.0). We next
looked at just the morning cortisol levels between the patient
groups by excluding the control group but found no signiﬁcant
difference (t24¼2.4, p¼0.2). There was no correlation between
UPDRS off score and baseline cortisol levels (all p values >0.4).
Risk task
Participants were tested twice on a behavioural task that
assessed risk taking behaviour
15 once off medication and once on
medication. Cortisol samples were taken just before each
administration of the task. The task assessed the extent to
which participants preferred large, low probability rewards to
smaller more probable rewards. We have reported detailed
analyses of the behavioural results previously, the main ﬁnding
Table 1 Characteristics of patients and healthy controls
Control group PDLICB group PD+ICB group t value, F value, c
2 p Value
Participants in total (n) 14 13 15
Gender (male) 6 11 10 c
2¼5.2, df¼2 0.075
Age (years)
At time of testing 58636 4 625 6 63F ¼2.5, df¼2 0.09
At disease onset e 52624 3 63t ¼2.6, df¼24 0.014*
Disease duration (years) e 11621 2 62t ¼0.4, df¼24 0.7
Pathological gambling ee 9
Hypersexuality ee 6
Compulsive shopping ee 5
Binge eating ee 4
Punding ee 2
Morning L-dopa dose (mg) e 170622 185625 t¼0.4, df¼24 0.6
Total L-dopa dose (mg) e 580674 6256100 t¼0.3, df¼24 0.7
LEU dose (mg) e 722685 7976100 t¼0.5, df¼24 0.6
DA (patients) e 85c
2¼1.6, df¼1 0.2
UPDRS off medication e 25613 2 64t ¼1.9, df¼24 >0.07
UPDRS on e 14621 9 63t ¼1.8, df¼24 0.08
Average improvement in UPDRS (%) e 44 41
All values are mean6SEM.
*Signiﬁcant difference.
DA, dopamine agonists; ICB, impulsive compulsive behaviour; LEU, L-dopa equivalent units; PD, Parkinson’s disease; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale.
Figure 2 (A) Diurnal cortisol levels of all three groups. (B) Cortisol levels between Parkinson’s disease patients without (PD ICB) and with (PD+ICB)
impulsive compulsive behaviour. All values are mean (61 SE). Although not signiﬁcantly different, baseline morning cortisol levels were lower in the
PD+ICB group.
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relative to controls.
17 Here we focus on the relationship between
cortisol and behaviour in the task. In the PD+ICB group, there
was a signiﬁcant correlation between change in risk from the
ﬁrst to the second test session (from the off medication state to
the on medication state) and change in cortisol levels measured
just before each test session (r¼ 0.617, p¼0.0144, n¼15).
Speciﬁcally, increased risk preference was associated with
increased cortisol levels. In the PD ICB group, the correlation
was not signiﬁcant (r¼0.166, p¼0.669, n¼11). Furthermore, the
correlation coefﬁcients were signiﬁcantly different between the
PD ICB and the PD+ICB groups (Z¼1.99, p¼0.047) such that
there was a signiﬁcantly stronger correlation in the PD+ICB
group than in the PD ICB group.
DISCUSSION
As expected, cortisol levels were found to be highest in the
morning in all participants and decreased over the day (ﬁgure 2).
Furthermore, we found signiﬁcantly higher daily salivary cortisol
levels in PD ICB patients compared with healthy controls but
no difference between PD+ICB patients and controls.
Increased irritability and lability, higher scores of disinhibition
and novelty seeking and a previous history of addictive behav-
iours have been reported in PD+ICB patients.
12 26 Furthermore,
all PD+ICB patients had higher schizotypy scores, which is
a personality trait related to the risk for psychosis, than
controls.
27 In this study, it is not possible to determine whether
changes in cortisol are a cause or effect of the impulsive
compulsive behaviours. However, impulsiveness, carelessness
and aggressive behaviour have been associated with attenuated
cortisol levels in adolescents and adults.
13 28e30 Impulsive adults
with illicit drugs abuse,
14 patients with antisocial behaviour
31 32
and controls with reduced negative feedback learning
33 also had
lower cortisol levels. Increased temporal discounting, the
tendency to choose earlier, smaller over delayed, larger rewards
has been found only in PD+ICB patients
27 and has been asso-
ciated with attenuated cortisol levels in healthy volunteers.
34
Various studies have also shown impairment in feedback
learning in PD+ICB patients.
17 35 36
However, we did not ﬁnd any difference between the two
patient groups and between the control and PD+ICB groups.
Previous studies found sustained elevated cortisol levels in
Aborigines after receiving their wages which they planned to
gamble with.
37 Therefore, the expectance of being tested and the
subsequent modest monetary reward for completing the study
could have led to an increase in baseline cortisol levels in PD+
ICB patients. Another possible explanation is that PD itself is
associated with increased cortisol levels
5 while personality traits
typical of PD+ICB patients are linked with lower cortisol levels.
This might explain why we did not ﬁnd any difference between
PD+ICB patients and the two other groups. Critically, we
observed a change of direction of cortisol levels only in the
PD+ICB group during gambling. This change of direction
in cortisol levels following a stressor has been linked with
antisocial behaviour.
30
We have reported previously that all PD patients were more
risk prone on medication compared with controls, with
a subgroup of PD+ICB with pathological gambling taking the
most risky decisions.
17 When correlating changes in cortisol
levels with risk taking behaviour, we found a signiﬁcant inter-
action in the PD+ICB group but not in the PD ICB group,
despite both groups showing similar performance on the risk
task. Our ﬁndings are consistent with previous studies in male
non-PD gamblers showing a rise in salivary cortisol levels
16 38
and blood cortisol levels
39 during gambling. Acutely raised
cortisol has been linked with anticipation of increased chances of
making money and can be euphorogenic.
40 41 Alcohol and
nicotine induce an increase in cortisol levels
84 2and addicts have
an increased activation of the hypothalamicepituitaryeaxis
during drug intake.
8 Several preclinical studies have also shown
that cortisol acts as a positive reinforcer and causes addiction.
43
Self-administration of cocaine leads to elevated cortisol levels in
rodents,
9 non-human primates
44 and humans.
45
Our ﬁndings, with a relative increase in cortisol in PD+ICB
during a risk task, further strengthen the links between biolog-
ical and drug addictions. This ﬁnding in a PD population is
especially interesting since L-dopa has a dual effect on cortisol
and behaviour. It increases risk behaviour in all PD patients
17
and high doses of L-dopa can reduce cortisol levels.
24 The latter
ﬁnding contrasts with our results but in this study by Muller
et al, a control group was not included, morning samples were
obtained at a time of the day when cortisol levels decrease
fastest and no information on circadian cortisol levels was
provided.
To our knowledge, this is the ﬁrst study that has tested sali-
vary samples in PD+ICB patients. Our results suggest that in
general, cortisol levels are elevated in PD ICB patients
compared with controls but not in the PD+ICB group. This is in
keeping with the literature which links lower cortisol levels with
antisocial behaviour, and further links ICBs with substance
addiction. Additionally, we found a signiﬁcant correlation
between risk taking behaviour and cortisol levels in the PD+ICB
group with higher cortisol levels being associated with risk prone
behaviour but no signiﬁcant interaction in the PD ICB group.
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